Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcellx, Inc. - Common Stock (NQ: ACLX )

51.38 -1.44 (-2.73%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 631,751
Open 51.52
Bid (Size) 49.20 (1)
Ask (Size) 55.35 (1)
Prev. Close 52.82
Today's Range 49.66 - 51.97
52wk Range 30.74 - 75.10
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Peering Into Arcellx's Recent Short Interest
Via Benzinga
Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Arcellx, Inc.
Via Business Wire

Performance

YTD
-8.50%
-8.50%
1 Month
-25.35%
-25.35%
3 Month
-8.51%
-8.51%
6 Month
+58.73%
+58.73%
1 Year
+25.32%
+25.32%

More News

Read More
Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
From Arcellx, Inc.
Via Business Wire
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
Via Benzinga
Arcellx Analysts Boost Their Forecasts After Q4 Results
Via Benzinga
Needham Maintains Buy Rating for Arcellx: Here's What You Need To Know
Via Benzinga
Where Arcellx Stands With Analysts
Via Benzinga
The 3 Biotech Stocks That Could Make Your February Unforgettable
Via InvestorPlace
Decoding Bearish Analog And The Warning Signs You Can't Ignore
Via Talk Markets
Topics Stocks
Exposures US Equities
Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market
Via InvestorPlace
Exposures Product Safety
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024
Via Benzinga
Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development
Via InvestorPlace
Why Johnson Controls International Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Blood Cancer Player Arcellx's Lead Product Exceeds Expectations, Analysts Say
Via Benzinga
Chart Of The Day: Arcellx - Reimagining Cell Therapy
Via Talk Markets
3 Biotech Stocks That Could Be Multibaggers in the Making
Via InvestorPlace
Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead
Via Investor's Business Daily
Kite and Arcellx Announce Expansion in Strategic Partnership
From Gilead Sciences, Inc.
Via Business Wire
Why Is Blood Cancer Focused Arcellx Stock Trading Higher Today?
Via Benzinga
7 Biotech Stocks to Get In Now Before Investors Catch On
Via InvestorPlace
Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Starbucks, Teleflex, Roku, Shopify And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs
Via InvestorPlace
Analysts Stay Bullish On Arcellx's CART-ddBCMA's Long-term Therapeutic Potential
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.